© 2021 MJH Life Sciences and Neurology Live. All rights reserved.
© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
April 20, 2021
The dean at the University of Exeter Medical School discussed the questions related to treating dementia-related psychosis and the options available.
Patient/guardian decision, adverse event, and physician decision were the 3 noted reasons for discontinuation with either ofatumumab or teriflunomide.
In an AAN plenary talk, Mark H. Tuszynski, MD, PhD, detailed the work he and colleagues have done to push stem cell therapy from the lab to the clinic to improve care for spinal cord injury.
Researchers analyzed disparities in stroke rehab and found that women and African Americans had the lowest functional performance.
The chief of Movement Disorders Division at the University of Miami Miller School of Medicine discussed some of the recent focused efforts to uncover more about Parkinson disease and what is on the horizon.
Patients with a previous history of cardiovascular risks experienced similarly low number of cardiovascular events with treatment of fremanezumab compared with placebo.
April 19, 2021
In total, 50% of patients eligible for device-aided therapies did not report having any discussion with providers about future device-aided therapies.
The 2021 AAN Meeting Hot Topics plenary focused on neurological facets of COVID-19, and featured insight from Anthony Fauci, MD, of NIAID, and Walter Koroshetz, MD, of NINDS, among others.
The vascular neurology fellow at the University of Maryland Medical Center discussed strategies to improve stroke care efficiency in women and African Americans.
An AAN session included presentations of research on the latest advancements and knowledge in neuromodulation for patients with these disorders.